Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Approx 3.5 million warrants expiring on August 14, 2024

<< Previous

Bullboard Posts

Next >>

Comment by spesestsemperon Aug 14, 2024 7:47pm

58 Views

Post# 36179598

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Approx 3.5 million warrants expiring on August 14, 2024

What you are saying is that the filings are wrong . Think about it for a minute , why would they only mention the 64035 from the 2019 . What? did they just think not to mention the others . Your the one that made the statement of 3.5 million expiring today and you can't back that up with anything recent . I have to go by what the company filed . Think I will go by the filings other than what you proclaim . The purpose of these boards is to have discussions of the company involved . Sorr if that bothers you

<< Previous

Bullboard Posts

Next >>

FLYHT and WestJet partner on weather forecasting